Treatment costs in hodgkin's disease: A cost-utility analysis

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1498-1503

  Norum, J ^a   Angelsen, V ^b   Wist, E ^a   Olsen, J A ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

, quality adjusted life years; Hodgkin's disease; Treatment costs

Indexed keywords

EID: 33748467176     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Norum J, Wist E. Psychological distress in survivors of Hodgkin's disease. Support Care Cancer 1996, 4 (in press).
2. Norum J, Wist E. Treatment of Hodgkin's disease in a small oncological unit. Eur J Haematol 1993, 50, 297-298.
3. Norum J, Bremnes RM, Wist E. The ChlVPP regimen, a risk factor for herpes zoster virus infection in patients treated for Hodgkin's disease. Eur J Haematol 1994, 53, 51-53.
4. Williams A. EuroQol - a new facility for the measurement of health related quality of life. The EuroQol group. Health Policy 1990, 16, 199-208.
5. Angelsen A. DRG and QALY. An Economical Analysis of Hospital Treatments. Tromsø, Department of Economics, University of Tromsø, 1995.
6. DeVita VT, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long term follow up of MOPP treated patients at NCI. Ann Intern Med 1980, 92, 587-595.
7. Longo DL, Young RL, Wesley M, et al. Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1986, 4, 1295-1306.
8. Koonanschap MA, Vanlnevald BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992, 34, 1005-1010.
9. Olsen JA. Production gains: should they count in health care evaluations? Scotts J Political Econ 1994, 41, 69-84.
10. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977, 296, 716-721.
11. Deusch CE, Lasala MR, Smith TJ, et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 1992, 10, 200-209.
12. Williams C, Coyle D, Gray A, et al. European School of Oncology Advisory Report to Commission of the European Communities for the Europe Against Cancer Programme. Cost-effectiveness in cancer care. EurJ Cancer 1995, 31A, 1410-1424.
13. Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies, an issue for debate? Pharm Econ 1992, 2, 153-162.
14. Katz DA, Welch HG. Discounting in cost-effectiveness analysis of healthcare programmes. Pharm Econ 1993, 4, 276-285.
15. Olsen JA. Time preferences for health gains. An empirical investigation. Health Econ 1993, 2, 257-265.
16. Williams A. Coronary artery bypass grafting, an economical appraisal. Br Med J 1985, 291, 326-329.
17. Smith RD, Hall J, Gumey H, et al. A cost-utility approach to the use of fluorouracil and levamisole as adjuvant chemotherapy for Dukes C colonic carcinoma. Med J Aust 1993, 158, 319-321.
18. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision analysis model. N Engl J Med 1991, 324, 161-168.
19. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993, 11, 771-776.
20. Epstein RJ. Does the breast dollar make sense? Eur J Cancer 1992, 28, 486-491.
21. Norum J, Angelsen V. Chemotherapy in gastric cancer. An economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-flourouracil) regimen. J Chemother 1995, 7, 455-459.